1. Dr David Ribeiro, CEO
February 3rd, 2016

2. Who we are
Award-winning biotechnology company founded in 2013 as a spin-out of Queen’s University Belfast
MISSION: Utilise our proprietary ProteaseTag™ technology to develop a range of products for the capture, detection and measurement of active protease biomarkers of disease
Secured close to £1M in grants to date:
NISP Connect 25K Award (2013), Proof of Concept Awards (Invest NI)
Horizon 2020 Phase I Award (2014)
Confidence in Concept (Medical Research Council)
Cystic Fibrosis Foundation (USA)
Seed Investors: QUBIS (25%) & NetScientific plc (56%)

3. Identification of an active problem
Active proteases are of biomedical and pharmaceutical importance
Diagnostic and prognostic value:
Drug targets and Biomarkers of disease activity

4. Innovative solutions to an active problem
ProteaseTags™
Irreversibly capture a specific active protease
Provide tools for the detection and quantification of the activity of a single protease species within a complex biological sample
Potential to be incorporated into a number of technology platforms

5. Active markets requiring smart solutions
Clinical/
Point of Care Tests
DEVELOPMENT OF LATERAL FLOW DEVICES WITH ASSOCIATED HAND-HELD READER TECHNOLOGY
ProteaseTagTM Immunoassays
KIT SALES
SERVICE PROVISION
DRUG DISCOVERY
LICENCING OPPORTUNITIES

6. The Opportunity Protease Target: Neutrophil elastase (NE)
Established biomarker of infection & inflammation/therapeutic target
Predictive of lung function decline
Market: CF & COPD
Both progressive lung diseases with cycles of inflammation/infection
Early identification of an impending exacerbation “Golden window”
Product: NEATstik™ (Neutrophil Elastase Airways Test)
First-to-market, Point-of-Care test
Rapid, easy testing at clinic OR within home
Improve patient health/outcomes
Reduce hospitalisations and total health costs

7. NEATstikTM could change clinical practice7
NEATstikTM could change clinical practice
Current Practice
NEATstikTM
Symptom-led
Increase in respiratory symptoms
Sputum production, colour & microbiology
Risk of emergency hospital admission
2 weeks i.v. antibiotics
Routine monitoring
Early detection of NE prior to escalation of symptoms
Prodromal phase up to 2 weeks
Pre-emptive home treatment
Oral antibiotics
NEGATIVE OUTCOMES
Hospitalisation
Invasive treatment
Increased frequency of exacerbation
Progressive deterioration of patient
High costs
POSITIVE OUTCOMES
Reduction in need for hospital beds
Oral treatments at home
Reduced exacerbations*
Rate of pulmonary decline stalled
Benefits to patients and healthcare provider
*A reduction of 5% in COPD exacerbations would be expected to save the NHS £16million pa

8. Pharma customers secured:8
ProteaseTag™ Active NE immunoassay
Pharma customers secured:
First sales & reorders
First in class product
Research use only (RO) tests: high throughput, lab-based tests
Customer: Academic laboratories, pharma and clinical research organisations (CROs) supporting clinical trials

9. Development of a novel assay for the detection of active Neutrophil Elastase in patients with COPD
NE was measured in 20 matched sputum samples from COPD patients when stable and during exacerbation
Levels of active NE were found to double at exacerbation
Significantly, active NE when measured by ProteaseTag™ Immunoassay showed a higher number of associations with other markers of inflammation such as IL1-b and TNF-a than when measured using a standard NE substrate
Moffitt KL, Walker, B, Chalmers, J, Ribeiro, D and Martin, SL, P102, British Thoracic Society, December 2015

10. Product Pipeline 10 Activities Nov Dec Jan Feb Mar Apr May Jun Jul Aug
Sep
Oct
NE Immunoassay
Commercialisation
Product A Immunoassay for Pulmonary Fibrosis
Development
Product B Immunoassay for CF and COPD
Product C Immunoassay for ARDS
2015
2016
2017

11. 2016: Organogram (from end of June)
CEO
CSO
(part-time)
Senior Project Manager
SALES & MARKETING Manager
MSL
Technical
To be appointed Q1 2016
To be appointed Q2 2016
Technical (Chemist)
technical 11

12. 12
Key 2016 Activities
Complete NEATstik development and initiate CE marking process by end of 2016
Maximise usage of NE Immunoassay
Invest in infrastructure to minimise reliance on third party suppliers
Progress R&D pipeline to enable further commercial immunoassay launches during
Series A fundraising round planned for 2H 2016

13. CONTACT Dr David Ribeiro ProAxsis Ltd 63 University Road13
CONTACT
Dr David Ribeiro
ProAxsis Ltd
63 University Road
Belfast BT7 1NF
Phone: +44 (0)
Follow us on Linked In and